Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Ken-ichiro Seino"'
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTInterleukin-34 (IL-34) has been known as a factor that is involved with tumor progression and therapeutic resistance. However, there are limitations to addressing the mechanism of how IL-34 induces therapeutic resistance. Here, we show a mech
Externí odkaz:
https://doaj.org/article/444988661bf44caf8e8c6521c59364dd
Autor:
Nabeel Kajihara, Yoshino Tanaka, Riko Takeuchi, Takuto Kobayashi, Masafumi Tanji, Tsukasa Ataka, Shiho Nakano, Taisho Yamada, Akinori Takaoka, Yoshinori Hasegawa, Ken-Ichiro Seino, Haruka Wada
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTAmong cancer immunotherapy, which has received great attention in recent years, cancer vaccines can potentially prevent recurrent tumors by using the exquisite power and specificity of the immune system. Specifically, whole tumor cell vaccine
Externí odkaz:
https://doaj.org/article/a2e96883e0bf4974952587959ad0e6d0
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background The cancer stem cell theory proposes that tumor formation in vivo is driven only by specific tumor-initiating cells having stemness; however, clinical trials conducted to test drugs that target the tumor stemness provided unsatisfactory re
Externí odkaz:
https://doaj.org/article/ccdcee806cc94ceeacaa7d55b876fae2
Autor:
Tomoki Kamatani, Ryo Otsuka, Tomoki Murata, Haruka Wada, Takeshi Takahashi, Akihiro Mori, Soichiro Murata, Hideki Taniguchi, Ken-ichiro Seino
Publikováno v:
Inflammation and Regeneration, Vol 42, Iss 1, Pp 1-13 (2022)
Abstract Background Off-the-shelf major histocompatibility complex (MHC)-matched iPS cells (iPSC) can potentially initiate host immune responses because of the existence of numerous minor antigens. To suppress allo-immune responses, combination of im
Externí odkaz:
https://doaj.org/article/921a43b21ced413aa7e86b9447892ae7
Autor:
Ken-ichiro Seino
Publikováno v:
Inflammation and Regeneration, Vol 42, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/6251e6f862a448efbf06c9bcdec09d4f
Autor:
Nanumi Han, Delnur Anwar, Naoki Hama, Takuto Kobayashi, Hidefumi Suzuki, Hidehisa Takahashi, Haruka Wada, Ryo Otsuka, Muhammad Baghdadi, Ken-ichiro Seino
Publikováno v:
Inflammation and Regeneration, Vol 40, Iss 1, Pp 1-10 (2020)
Abstract Background Interleukin (IL)-34 acts as an alternative ligand for the colony-stimulating factor-1 receptor and controls the biology of myeloid cells, including survival, proliferation, and differentiation. IL-34 has been reported to be expres
Externí odkaz:
https://doaj.org/article/636e3f9f24664908a7f1f2b5218ecf1e
Autor:
Ryo Otsuka, Ken-ichiro Seino
Publikováno v:
Inflammation and Regeneration, Vol 40, Iss 1, Pp 1-6 (2020)
Abstract An emerging, rapidly spreading coronavirus SARS-CoV-2 is causing a devastating pandemic. As we have not developed curative medicine and effective vaccine, the end of this life-threatening infectious disease is still unclear. Severe COVID-19
Externí odkaz:
https://doaj.org/article/cc7f2e283cce4dc386394d512b91fa1f
Publikováno v:
Inflammation and Regeneration, Vol 40, Iss 1, Pp 1-9 (2020)
Abstract The development of pluripotent stem cell (PSC)-based technologies provides us a new therapeutic approach that generates grafts for transplantation. In order to minimize the risk of immune reaction, the banking of induced pluripotent stem cel
Externí odkaz:
https://doaj.org/article/e87f8856f3244333956fec7bce9772be
Autor:
Naoki Hama, Takuto Kobayashi, Nanumi Han, Fumihito Kitagawa, Nabeel Kajihara, Ryo Otsuka, Haruka Wada, Hee-kyung Lee, Hwanseok Rhee, Yoshinori Hasegawa, Hideo Yagita, Muhammad Baghdadi, Ken-ichiro Seino
Publikováno v:
iScience, Vol 25, Iss 1, Pp 103713- (2022)
Externí odkaz:
https://doaj.org/article/3c647d2d12494482a43f376250cefb59
Autor:
Nanumi Han, Hye Yoon Jang, Naoki Hama, Takuto Kobayashi, Ryo Otsuka, Haruka Wada, Ken-ichiro Seino
Publikováno v:
STAR Protocols, Vol 2, Iss 2, Pp 100460- (2021)
Summary: Previously, we identified a therapy-resistant role of IL-34 in an immune checkpoint blockade in murine models. To investigate whether a similar mechanism is applicable in human tumors as well, we used this protocol for the selection of IL-34
Externí odkaz:
https://doaj.org/article/a2cb2e4ed81a4be184c077d74c0b7c85